Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Jarvenpaa – page 6

403 clinical trials in Jarvenpaa, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Jarvenpaa at a glance
403
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

403 trials in Jarvenpaa

Open in trial search

Hyperkalaemia

Recruiting

A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Patiromer
  • Sponsor:Vifor Pharma Inc.

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
  • Sponsor:Pfizer Inc.

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Jarvenpaa

What the registry says about research in the country

01 Respiratory Virus Prevention

Innovative research focusing on respiratory syncytial virus (RSV) and influenza vaccines, evaluating new preventive approaches for both young and elderly populations.

  • RSV vaccine development for seniors
  • Influenza vaccine efficacy studies
  • Combined viral protection research

Multiple clinical trials are exploring breakthrough vaccine technologies, including mRNA platforms.

02 Meningococcal Disease Research

Comprehensive studies on meningococcal vaccines targeting multiple disease strains, with particular focus on protecting infants and young children.

  • Pentavalent vaccine development
  • Long-term immunity studies
  • Pediatric vaccination protocols

Research aims to enhance protection against various meningococcal serogroups through innovative conjugate vaccines.

03 Viral Disease Prevention

Advanced research into preventing cytomegalovirus and herpes zoster infections, utilizing cutting-edge vaccine technologies.

  • CMV prevention strategies
  • Herpes zoster vaccine efficacy
  • Pneumococcal protection studies

These trials focus on developing robust immune responses in specific target populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.